Prime Capital Investment Advisors LLC Invests $37,000 in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

Prime Capital Investment Advisors LLC purchased a new position in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) in the 4th quarter, HoldingsChannel.com reports. The firm purchased 22,053 shares of the company’s stock, valued at approximately $37,000.

Several other large investors also recently modified their holdings of the stock. Cambridge Investment Research Advisors Inc. purchased a new position in Ginkgo Bioworks in the 1st quarter valued at approximately $43,000. Atria Wealth Solutions Inc. purchased a new position in Ginkgo Bioworks in the 2nd quarter valued at approximately $30,000. Creative Planning purchased a new position in Ginkgo Bioworks in the 4th quarter valued at approximately $25,000. Silverlake Wealth Management LLC purchased a new position in Ginkgo Bioworks in the 4th quarter valued at approximately $25,000. Finally, Captrust Financial Advisors grew its stake in Ginkgo Bioworks by 226.7% in the 1st quarter. Captrust Financial Advisors now owns 16,333 shares of the company’s stock valued at $66,000 after buying an additional 11,333 shares in the last quarter. Hedge funds and other institutional investors own 78.63% of the company’s stock.

Insider Activity

In other news, insider Mark E. Dmytruk sold 51,169 shares of Ginkgo Bioworks stock in a transaction on Tuesday, April 2nd. The shares were sold at an average price of $1.05, for a total transaction of $53,727.45. Following the completion of the sale, the insider now directly owns 865,079 shares of the company’s stock, valued at approximately $908,332.95. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, insider Mark E. Dmytruk sold 39,569 shares of Ginkgo Bioworks stock in a transaction on Friday, February 2nd. The shares were sold at an average price of $1.21, for a total transaction of $47,878.49. Following the completion of the sale, the insider now directly owns 761,737 shares of the company’s stock, valued at approximately $921,701.77. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Mark E. Dmytruk sold 51,169 shares of Ginkgo Bioworks stock in a transaction on Tuesday, April 2nd. The stock was sold at an average price of $1.05, for a total transaction of $53,727.45. Following the sale, the insider now directly owns 865,079 shares of the company’s stock, valued at $908,332.95. The disclosure for this sale can be found here. Company insiders own 15.05% of the company’s stock.

Ginkgo Bioworks Price Performance

DNA opened at $1.01 on Monday. The company has a fifty day moving average price of $1.23 and a 200-day moving average price of $1.40. The firm has a market capitalization of $2.17 billion, a P/E ratio of -2.15 and a beta of 1.35. Ginkgo Bioworks Holdings, Inc. has a one year low of $0.99 and a one year high of $2.55.

Ginkgo Bioworks (NYSE:DNA) last released its quarterly earnings results on Thursday, February 29th. The company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.01). The firm had revenue of $34.76 million for the quarter, compared to analysts’ expectations of $40.37 million. Ginkgo Bioworks had a negative net margin of 355.08% and a negative return on equity of 48.23%. The firm’s revenue for the quarter was down 64.6% on a year-over-year basis. During the same quarter last year, the firm earned ($0.04) earnings per share. On average, analysts expect that Ginkgo Bioworks Holdings, Inc. will post -0.32 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on DNA. The Goldman Sachs Group reduced their price objective on shares of Ginkgo Bioworks from $1.25 to $1.10 and set a “sell” rating for the company in a research note on Monday, January 22nd. TD Cowen reduced their price objective on shares of Ginkgo Bioworks from $7.00 to $3.00 and set an “outperform” rating for the company in a research note on Friday, March 1st. One investment analyst has rated the stock with a sell rating, three have given a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Ginkgo Bioworks presently has a consensus rating of “Hold” and an average target price of $2.20.

Ginkgo Bioworks Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.